These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 2828537

  • 1. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    Knoll J.
    J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
    [Abstract] [Full Text] [Related]

  • 2. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J.
    Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.
    Paterson IA, Juorio AV, Berry MD, Zhu MY.
    J Pharmacol Exp Ther; 1991 Sep; 258(3):1019-26. PubMed ID: 1679846
    [Abstract] [Full Text] [Related]

  • 4. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J.
    Vopr Med Khim; 1997 Sep; 43(6):482-93. PubMed ID: 9503565
    [Abstract] [Full Text] [Related]

  • 5. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
    Engberg G, Elebring T, Nissbrandt H.
    J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.
    Zsilla G, Földi P, Held G, Székely AM, Knoll J.
    Pol J Pharmacol Pharm; 1986 Nov; 38(1):57-67. PubMed ID: 3020531
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Trace amines inhibit the electrically evoked release of [3H]acetylcholine from slices of rat striatum in the presence of pargyline: similarities between beta-phenylethylamine and amphetamine.
    Baud P, Arbilla S, Cantrill RC, Scatton B, Langer SZ.
    J Pharmacol Exp Ther; 1985 Oct; 235(1):220-9. PubMed ID: 3930699
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
    Knoll J, Miklya I.
    Arch Int Pharmacodyn Ther; 1994 Oct; 328(1):1-15. PubMed ID: 7893186
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
    Knoll J.
    J Am Geriatr Soc; 1992 Aug; 40(8):839-47. PubMed ID: 1634730
    [Abstract] [Full Text] [Related]

  • 16. The pharmacology of (-)deprenyl.
    Knoll J.
    J Neural Transm Suppl; 1986 Aug; 22():75-89. PubMed ID: 3097262
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I, Youdim MB, Finberg JP.
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [Abstract] [Full Text] [Related]

  • 20. The action of (-) deprenyl on monoamine turnover rate in rat brain.
    Zsilla G, Knoll J.
    Adv Biochem Psychopharmacol; 1982 Oct; 31():211-7. PubMed ID: 6805258
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.